Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.

Gautschi, Mirja; Oberholzer, Patrick Antony; Baumgartner, Marc; Gadaldi, Karolina; Yawalkar, Nikhil; Hunger, Robert (2016). Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. Journal of the American Academy of Dermatology, 74(1), 81-87.e1. Elsevier 10.1016/j.jaad.2015.08.031

[img] Text
Hunger 3.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img]
Preview
Text
Lentigo_maligna_Submission_170815.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (113kB) | Preview
[img]
Preview
Text (Table 1)
Table_1m.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (58kB) | Preview
[img]
Preview
Text (Table 2)
Table_2m.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (33kB) | Preview
[img]
Preview
Image (Figure 1)
Figure_1_gross.tif - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (739kB) | Preview
[img]
Preview
Image (Figure 2)
Figure 2 arrows-1.tif - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (2MB) | Preview
[img]
Preview
Image (Figure 3)
Figure_3.tif - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (175kB) | Preview
[img]
Preview
Image (Figure supplementary)
Figure_supplementary_gross.tif - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (307kB) | Preview

BACKGROUND More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM). OBJECTIVE We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod. METHODS This was a single-arm, open-label, nonrandomized, prospective study. RESULTS Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes. LIMITATIONS Our study was a single-center, nonrandomized study. CONCLUSION An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Oberholzer, Patrick Antony; Baumgartner, Marc; Gadaldi, Karolina; Yawalkar, Nikhil and Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0190-9622

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

09 Mar 2016 10:48

Last Modified:

14 Sep 2017 08:53

Publisher DOI:

10.1016/j.jaad.2015.08.031

PubMed ID:

26601565

Uncontrolled Keywords:

efficacy; follow-up; imiquimod; lentigo maligna; prognostic marker; recurrence; topical immunomodulators

BORIS DOI:

10.7892/boris.76277

URI:

https://boris.unibe.ch/id/eprint/76277

Actions (login required)

Edit item Edit item
Provide Feedback